louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00442494: Corticosteroids for the Prevention of Atrial Fibrillation After Cardiac Surgery
Official title: Feasibility of Corticosteroid in the Prevention of Atrial Fibrillation After Cardiac Surgery: A Prospective, Double-Blind Randomized Multicenter Trial
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Atrial Fibrillation
Keywords: Atrial fibrillation after cardiac surgery
Lead sponsor: Kuopio University Hospital
Sponsor class: OTHER
Collaborators: name: Tampere University Hospital
name: Oulu University Hospital
First posted: 2007-03-02
Enrollment: 1
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: Atrial fibrillation is the most common arrhythmia to occur after cardiac surgery. Inflammatory response may be one etiological factor.

We hypothesized that intravenous corticosteroid administration after cardiac surgery prevents AF after cardiac surgery.


Eligibility criteria: Inclusion Criteria:

* Patients scheduled to undergo their first on-pump CABG, aortic valve replacement or combined aortic valve replacement and CABG were enrolled.

Exclusion Criteria:

* Previous episodes of AF or flutter
* Uncontrolled diabetes mellitus
* Systemic mycotic infection
* Active tuberculosis
* Cushing's syndrome
* Psychotic mental disorder
* Herpes Simplex keratitis
* Serum creatinine exceeding 200 µg/ml
* Patients were also excluded if they had a history of previous peptic ulcer or thrombophlebitis.

Primary outcomes:
measure: Study couldn´t start due to investigator
timeFrame: Study couldn´t start due to investigator
Secondary outcomes:
measure: Study couldn´t start due to investigator
timeFrame: Study couldn´t start due to investigator
Other outcomes:
measure: Study couldn´t start due to investigator
timeFrame: Study couldn´t start due to investigator
Locations:
Study officials:
affiliation: Kuopio University Hospital
name: Jari Halonen, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Voltarelli JC, Couri CE, Stracieri AB, Oliveira MC, Moraes DA, Pieroni F, Coutinho M, Malmegrim KC, Foss-Freitas MC, Simoes BP, Foss MC, Squiers E, Burt RK. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2007 Apr 11;297(14):1568-76. doi: 10.1001/jama.297.14.1568.
citation: Halonen J, Halonen P, Jarvinen O, Taskinen P, Auvinen T, Tarkka M, Hippelainen M, Juvonen T, Hartikainen J, Hakala T. Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial. JAMA. 2007 Apr 11;297(14):1562-7. doi: 10.1001/jama.297.14.1562.
Clinical trial NCT02912494: A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Anemia
Lead sponsor: Kissei Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
Collaborators: name: JCR Pharmaceuticals Co., Ltd.
First posted: 2016-09-23
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT

Brief summary: The purpose of this study is to investigate the equivalence of JR-131 to Darbepoetin alfa and evaluate the safety of JR-131 in renal anemia patients with chronic kidney disease (CKD).


Eligibility criteria: Inclusion Criteria:

* Patients being treated with Darbepoetin alfa.

Exclusion Criteria:

* Patients having complication or history of a cardiovascular / lung / brain infarction.
* Patients having a pronounced hemorrhagic lesion.

Primary outcomes:
measure: Change from baseline in Hemoglobin level
timeFrame: 24 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Multiple Locations
country: Japan
Study officials:
References:
Clinical trial NCT05845294: A Study of the Effect of Short-term Structured Psychological Care in Patients
Official title: A Study of the Effect of Short-term Structured Psychological Care on the Level of Postoperative Stigma in Patients With Colorectal Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Colorectal Cancer
Lead sponsor: Zunyi Medical College
Sponsor class: OTHER
First posted: 2023-05-06
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The study explored the effects of short-term structured psychological care on the level of postoperative psychological resilience, stigma, anxiety and depression in patients with colorectal cancer colostomy.


Eligibility criteria: Inclusion Criteria:

1. voluntary participation in the study and ability to cooperate with treatment and care;
2. patients who were to undergo enterostomy;
3. age ≥18 years;
4. consciousness (being able to complete the questionnaire alone or able to answer the questions correctly);
5. social impact scale (SIS) score ≥24.

Exclusion Criteria:

1. Critically ill and unable to cooperate with the study;
2. Impaired cognitive function that affects communication;
3. Patients with other organic diseases in combination.

Primary outcomes:
measure: Anxiety of patients was assessed by Chinese version of the Mental Toughness Scale
timeFrame: 1 month
measure: Anxiety of patients was assessed by the Social Impact Scale
timeFrame: 1 month
measure: Anxiety of patients was assessed by Hospital Anxiety and Depression Scale
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Zunyi
country: China
facility: Zunyi Medical College
state: Guizhou
Study officials:
References:
Clinical trial NCT03663894: Clinical Characteristics and Outcomes of Relapsed Follicular Lymphoma After Autologous Stem Cell Transplantation at Rituximab Era
Official title: Clinical Characteristics and Outcomes of Relapsed Follicular Lymphoma After Autologous Stem Cell Transplantation at Rituximab Era
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Patient's Outcome Prognostic Factors
Keywords: Autologous stem cell transplantation
rituximab
Follicular Lymphoma
prognosis
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2018-09-10
Enrollment: 95
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 95 consecutive patients who fulfilled the eligibility criteria for this study were reviewed retrospectively with data cut-off of December 2014. FL patients in relapse after ASCT. All patients presented at diagnosis a grade 1, 2, or 3A follicular lymphoma confirmed by either excisional or core needle biopsy.

Brief summary: Introduction High dose chemotherapy followed by Autologous Stem Cell Transplantation (ASCT) is a therapeutic option in follicular Lymphoma after first line treatment failure. The clinical characteristics and outcome of FL patients who relapsed after HDT+ASCT and therapeutic management in the rituximab era are not well known and may represent a difficult challenge.

Patients and Methods: The investigators conducted a retrospective analysis of FL patients who relapsed after HDT+ASCT in four French centers treated between 2000 and 2014. Clinical records were reviewed for clinical characteristics and treatment strategy at relapse. The investigators aimed to identify prognostic factors related to patient's outcome.


Eligibility criteria: Inclusion Criteria:

* they were older than 18 years
* presented FL at diagnosis (Grade 1, 2, or 3a).
* received high-dose therapy (HDT) with ASCT from 2000 to 2014

Exclusion Criteria:

1. they had already been treated with a 1st ASCT,
2. had a previous history of histological transformation before ASCT
3. if they were rituximab naive prior to ASCT.

Primary outcomes:
measure: Survival after relapse (SAR) post ASCT in follicular lymphoma
timeFrame: Year 6
Secondary outcomes:
measure: Histological Transformation at relapse
timeFrame: Year 6
measure: treatment of relapse
timeFrame: Year 6
Other outcomes:
Locations:
city: Pierre-Bénite
country: France
facility: Centre Hospitalier Lyon Sud, Hematology department
Study officials:
affiliation: Hospices Civils de Lyon
name: Pierre SESQUES, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03990194: Real-life Study of Patients After 3-months of Leuprorelin 5mg Implant in Prostate Cancer
Official title: Real-life Observational Study of Patients After 3-months of Leuprorelin 5mg Implant and Evaluation of Coping Strategies Among Patients With Prostate Cancer: LEPTO STUDY
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Prostate Cancer
Lead sponsor: RECORDATI GROUP
Sponsor class: INDUSTRY
First posted: 2019-06-18
Enrollment: 0
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with prostate cancer for whom the physician has decided to prescribe hormone therapy by subcutaneous leuprorelin implant 5 mg (Leptoprol®).

Brief summary: To improve the management of patients suffering from prostate cancer, Laboratoires BOUCHARA-RECORDATI wish to set up an observational study to document, in daily practice, and over a large population, the profile and clinical and biological follow-up of patients undergoing leuprorelin 5 mg implant as well as the conditions for implant placement. The evolution of these prostate cancer patients will be monitored on the basis of data available in daily practice, including testosterone values, PSA values, and factors that may influence disease progression, in order to objectify whether the observed results are consistent with those described in the clinical studies.

Detailed description: To improve the management of patients suffering from prostate cancer, Laboratoires BOUCHARA-RECORDATI wish to set up an observational study to document, in daily practice, and over a large population, the profile and clinical and biological follow-up of patients undergoing leuprorelin 5 mg implant as well as the conditions for implant placement. The evolution of these prostate cancer patients will be monitored on the basis of data available in daily practice, including testosterone values, PSA values, and factors that may influence disease progression, in order to objectify whether the observed results are consistent with those described in the clinical studies.

The psychological dimension of the management of patients with prostate cancer will also be addressed by evaluating the strategies used by patients to cope with their prostate cancer \[(Prostate Cancer Patients' Coping Strategies Questionnaire (PCPCSQ)\].

Eligibility criteria: Inclusion Criteria:

* Patients with prostate cancer for whom the physician has decided to prescribe hormone therapy by subcutaneous leuprorelin implant 5 mg (Leptoprol®).

Exclusion Criteria:

* Patient who have already participated in another study or those who do not wish to participate in this study.

Primary outcomes:
measure: The percentage of prostate cancer patients at 3 months who attained a testosteronemia threshold of ≤ 0.5 ng/mL following a 3-month treatment with leuprorelin 5 mg implant
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00490594: SeriACL™ Device Trial for Anterior Cruciate Ligament (ACL) Reconstruction
Official title: A Multi-Center Open Study to Evaluate the SeriACL™ Device for Primary Anterior Cruciate Ligament Repair
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Anterior Cruciate Ligament
Knee Injuries
Keywords: ACL
ligament
ACL injury
Lead sponsor: Serica Technologies, Inc.
Sponsor class: INDUSTRY
First posted: 2007-06-22
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The SeriACL device was developed as an alternative to an autograft (i.e., tissue that is taken from a patient's own body) or an allograft (i.e., tissue that is taken from a cadaver) for ACL reconstruction. The SeriACL device is made of silk yarns, knit and processed with SeriCoat™ surface treatment which makes it easier to wet the material. The SeriACL device is designed to be a temporary support structure to replace the torn ACL and to stabilize the knee joint following surgical repair. It is designed to use the body's own healing process to regenerate the patient's own new ligament tissue. As the new tissue grows and the support structure is needed less over time, the SeriACL device is bioresorbed (i.e., broken down) by the patient's body. The SeriACL device is designed to be installed with standard surgical techniques for ACL repair.

This study is designed to test the safety of the SeriACL device in primary total ACL repair in patients with a torn ACL. The study will evaluate whether repair of the ACL with the SeriACL device will return the knee to normal function and what, if any, side effects will occur.


Eligibility criteria: Inclusion Criteria:

* Complete ACL rupture
* Injured knee range of motion \>= 75% of contralateral knee
* MCL tear grading \<= 2
* Sign informed consent.

Exclusion criteria:

* Prior ACL reconstruction
* Complete PCL tear
* Locked bucket handle tear or complex tears of the menisci.
* Contralateral knee ligament injury
* Known joint disease
* Known allergy to silk
* Active drug or alcohol abuse
* Pregnant

Primary outcomes:
measure: Safety - measured by device related SAEs
timeFrame: 12 months
measure: KT-1000 Arthrometer
timeFrame: 12 months
Secondary outcomes:
measure: Knee Surveys
timeFrame: 12 months
measure: Return to Work
timeFrame: 12 months
Other outcomes:
Locations:
city: Heidelberg
country: Germany
facility: Atos Clinic
city: Heidelberg
country: Germany
facility: Heidelberg University
city: Oslo
country: Norway
facility: Ullevaal Hospital
Study officials:
affiliation: Ullevaal Hospital
name: Lars Engebretsen, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: ATOS Clinic, Heidelberg
name: Hans Paessler, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Heidelberg University
name: Holger Schmitt, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00979394: Evaluation of Diabetes Care at Austrian GPs
Official title: Diabetes Care Austria 2009
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Type 2 Diabetes
Keywords: Diabetes Care at GPs in Austria
Characteristic of diabetes patients at GPs in Austria
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
Collaborators: name: Bristol-Myers Squibb
First posted: 2009-09-18
Enrollment: 1513
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: GPs

Brief summary: This registery should show the medical care of patient with Type 2 Diabetes (T2D) at GP-offices. Furthermore data of co morbidities and risk factors should be evaluated. Objectives of this NIS (cross-sectional study) are:

* To evaluate which characteristics or co-morbidities are being existent for patient with T2D at GP level,
* To evaluate representative profile of patient with T2D in Austria,
* To evaluate which medical therapies are used.


Eligibility criteria: Inclusion Criteria:

* Diabetes mellitus type II

Exclusion Criteria:

* Diabetes mellitus type I
* Gestation diabetes
* Induced diabetes

Primary outcomes:
measure: Evaluate characteristics or co morbidities being existent for patient with T2D at GP
timeFrame: Once per patient
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: General Hospital Vienna
name: Bernhard Ludvig
role: STUDY_CHAIR
affiliation: Krankenanstalt Rudolfsstiftung
name: Guntram Schernthaner
role: STUDY_CHAIR
References:
Clinical trial NCT01312194: Periapical Healing After One or Two-visits to Endodontic Treatment in Adolescents Patients
Official title: Periapical Healing After One or Two-visits to Endodontic Treatment in Adolescents Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Periapical Periodontitis
Keywords: Periapical Periodontitis
Dental Pulp Necrosis
Root canal Therapy
Adolescent
Lead sponsor: Universidade Federal do Rio de Janeiro
Sponsor class: OTHER
First posted: 2011-03-10
Enrollment: 120
Sex: ALL
Minimum age (years): 11
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main objective of this study is the prevention and repair of apical periodontitis in lower molars with pulp necrosis after the execution of endodontic treatment in one or two visits in adolescent patients. Moreover, it is also observed the frequency of postoperative pain in endodontic treatment.

Detailed description: This project is developed in adolescent patients who have need of endodontic treatment in necrotic molars. The patients were randomly divided into two groups of treatment: one and two visits. The treatment protocol is the same for both groups, except the number of visits and the use of intra canal medication in the group treated in two visits. Patients will be followed clinically and radiographically for a minimum period of two years. The data was collected by the evaluation of postoperative pain and to determine the healing of periapical lesions, characterizing the success of the treatment.

Eligibility criteria: Inclusion Criteria:

1. Patients healthy
2. Not have taken analgesic, anti-inflammatory or antibiotic drugs during the 10 days prior to the beginning of treatment
3. Lower first or second permanent molars with complete root formation and dental pulp necrosis with or without symptoms

Exclusion Criteria:

1. Presence of periodontal diseases
2. Pulp calcification
3. Acute dent-alveolar abscesses
4. Hemorrhage in the canal after access

Primary outcomes:
measure: Healing Rate of one- versus two-visit endodontic treatment
timeFrame: Two years
Secondary outcomes:
measure: Postoperative pain of endodontic treatment
timeFrame: 60 days
Other outcomes:
Locations:
city: Rio de Janeiro
country: Brazil
facility: Federal University of Rio de Janeiro
Study officials:
affiliation: Universidade Federal do Rio de Janeiro
name: Patrícia A Risso, Dentist
role: PRINCIPAL_INVESTIGATOR
affiliation: Universidade Federal do Rio de Janeiro
name: Antonio JL Cunha, doctor
role: STUDY_DIRECTOR
References:
citation: Risso PA, Cunha AJ, Araujo MC, Luiz RR. Postobturation pain and associated factors in adolescent patients undergoing one- and two-visit root canal treatment. J Dent. 2008 Nov;36(11):928-34. doi: 10.1016/j.jdent.2008.07.006. Epub 2008 Sep 3.
citation: de Andrade Risso P, da Cunha AJ, de Araujo MC, Luiz RR. Postoperative pain and associated factors in adolescent patients undergoing two-visit root canal therapy. Aust Endod J. 2009 Aug;35(2):89-92. doi: 10.1111/j.1747-4477.2008.00134.x.
Clinical trial NCT01435460: Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)
Official title: A Clinical Safety and Efficacy Evaluation of Alrex® (Loteprednol Etabonate Ophthalmic Suspension, 0.2%) Versus Patanol (Olopatadine Hydrochloride Ophthalmic Solution, 0.1%) in the Treatment of Seasonal Allergic Conjunctivitis (SAC)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Seasonal Allergic Conjunctivitis
Keywords: ocular allergy
Lead sponsor: Bausch & Lomb Incorporated
Sponsor class: INDUSTRY
First posted: 2011-09-16
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is to evaluate the safety and efficacy of Alrex (LE ophthalmic suspension, 0.2%) versus Patanol (olopatadine hydrochloride ophthalmic solution, 0.1%) in the temporary relief of the signs and symptoms of Seasonal Allergic Conjunctivitis (SAC).


Eligibility criteria: Inclusion Criteria:

* Subjects who are diagnosed with acute SAC and experience at least grade 4 ocular itching and at least grade 2 bulbar conjunctival injection (redness) in each eye due to seasonal allergy at Visit 1.

Exclusion Criteria:

* Subjects who have a known hypersensitivity to the study medications or their components or contraindications to ocular corticosteroids.
* Subjects who use any of the disallowed medications throughout the duration of the study and during the period indicated prior to Visit 1.
* Subjects who have intraocular pressure (IOP) greater than 21 mm Hg in either eye or any type of glaucoma.
* Subjects who have a history of any severe/serious ocular pathology or medical condition that could result in the subject's inability to complete the study or affect the subject's safety or trial parameters.

Primary outcomes:
measure: Bulbar Conjunctival Injection
timeFrame: Change from baseline to day 15 (visit 3)
measure: Ocular Itching
timeFrame: Change from baseline to day 15 (visit 3)
Secondary outcomes:
measure: Bulbar Conjunctival Injection
timeFrame: Change from baseline to day 8 (visit 2)
measure: Ocular Itching
timeFrame: Change from baseline to day 8 (visit 2)
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: Bausch & Lomb Singapore
Study officials:
affiliation: Bausch & Lomb Incorporated
name: Esther Chu
role: STUDY_DIRECTOR
References:
citation: Gong L, Sun X, Qu J, Wang L, Zhang M, Zhang H, Wang L, Gu Y, Elion-Mboussa A, Roy L, Zhu B. Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients. Clin Ther. 2012 Jun;34(6):1259-1272.e1. doi: 10.1016/j.clinthera.2012.04.024. Epub 2012 May 23.
Clinical trial NCT00548860: Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients
Official title: A Multi-center, Randomized Controlled Study to Investigate the Safety and Tolerability of IV Ferric Carboxymaltose (FCM) vs Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Anemia
Lead sponsor: American Regent, Inc.
Sponsor class: INDUSTRY
First posted: 2007-10-24
Enrollment: 2018
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The Objective of this study is to study the safety of FCM in patients with anemia caused by Heavy Uterine Bleeding and the Post Partum state.


Eligibility criteria: Inclusion Criteria:

* Female with iron deficiency anemia
* Hg \</= 11 g/dL

Exclusion Criteria:

* Previous participation in a FCM trial
* Known Hypersensitivity to FCM
* History of anemia other that anemia due to heavy uterine bleeding or the post partum state
* current history of GI bleeding
* Received IV Iron within the month prior
* Anticipated need for surgery
* Malignancy history
* AST or ALT greater than normal
* Received an investigational drug within 30 days of screening
* Pregnant or sexually active females who are not willing ot use an effective form of birth control

Primary outcomes:
measure: Evaluate the Safety of the Maximum Administered Dose, 15 mg/kg (up to a Maximum 1,000 mg) of FCM Compared to SMC.
timeFrame: From Day 0 through 30 days after the last dose of study drug.
Secondary outcomes:
Other outcomes:
Locations:
city: Norristown
country: United States
facility: Luitpold Pharmaceuticals
state: Pennsylvania
Study officials:
References:
citation: Seid MH, Butcher AD, Chatwani A. Ferric Carboxymaltose as Treatment in Women with Iron-Deficiency Anemia. Anemia. 2017;2017:9642027. doi: 10.1155/2017/9642027. Epub 2017 Apr 13.